MX2015011671A - Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. - Google Patents
Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.Info
- Publication number
- MX2015011671A MX2015011671A MX2015011671A MX2015011671A MX2015011671A MX 2015011671 A MX2015011671 A MX 2015011671A MX 2015011671 A MX2015011671 A MX 2015011671A MX 2015011671 A MX2015011671 A MX 2015011671A MX 2015011671 A MX2015011671 A MX 2015011671A
- Authority
- MX
- Mexico
- Prior art keywords
- administration
- zoledronic acid
- steroids
- osteoarthritis
- prevent
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title abstract 5
- 238000011260 co-administration Methods 0.000 title abstract 4
- 150000003431 steroids Chemical class 0.000 title abstract 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004276 zoledronic acid Drugs 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revela una terapia de combinación para tratar la osteoartritis. La terapia de combinación incluye la co- administración de un esteroide y Ácido Zoledrónico. La coadministración de un esteroide reduce la producción de citocinas y, en consecuencia, reduce los efectos proinflamatorios del Ácido Zoledrónico. La co-administración del Ácido Zoledrónico con esteroides trata la osteoartritis y contribuye a prevenir el inicio de la osteoartritis en pacientes en riesgo de desarrollar osteoartritis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/791,685 US9012432B2 (en) | 2013-03-08 | 2013-03-08 | Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis |
| PCT/US2014/022169 WO2014138712A1 (en) | 2013-03-08 | 2014-03-07 | Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011671A true MX2015011671A (es) | 2016-05-12 |
| MX377447B MX377447B (es) | 2025-03-10 |
Family
ID=51488530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011671A MX377447B (es) | 2013-03-08 | 2014-03-07 | Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9012432B2 (es) |
| EP (1) | EP2964209B1 (es) |
| JP (2) | JP6839491B2 (es) |
| KR (1) | KR102253394B1 (es) |
| CN (1) | CN105324113B (es) |
| AU (1) | AU2014225373B2 (es) |
| BR (1) | BR112015021503B1 (es) |
| CA (1) | CA2941346C (es) |
| EA (1) | EA032067B1 (es) |
| ES (1) | ES2904365T3 (es) |
| MX (1) | MX377447B (es) |
| WO (1) | WO2014138712A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10913772B2 (en) | 2016-03-09 | 2021-02-09 | Kine Sciences Co., Ltd. | Peptide for preventing or treating inflammatory diseases and use thereof |
| KR101897122B1 (ko) | 2016-03-09 | 2018-09-10 | 주식회사 바이오펩 | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 |
| US10913771B2 (en) | 2016-03-09 | 2021-02-09 | Kine Sciences Co., Ltd. | Peptide for preventing or treating inflammatory diseases and use thereof |
| WO2017155234A1 (ko) | 2016-03-09 | 2017-09-14 | 주식회사 바이오펩 | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 |
| WO2017155233A1 (ko) | 2016-03-09 | 2017-09-14 | 주식회사 바이오펩 | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 |
| JP7127616B2 (ja) | 2019-06-04 | 2022-08-30 | 横河電機株式会社 | 情報処理装置、アラーム管理システム、及びアラーム管理方法 |
| WO2021163432A1 (en) * | 2020-02-12 | 2021-08-19 | Levolta Pharmaceuticals, Inc. | Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis |
| CN114028571B (zh) * | 2021-11-18 | 2023-04-28 | 中国医学科学院基础医学研究所 | 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE72816T1 (de) | 1986-11-21 | 1992-03-15 | Ciba Geigy Ag | Neue substituierte alkandiphosphonsaeuren. |
| US7018647B1 (en) * | 1999-12-27 | 2006-03-28 | Teikoku Seiyaku Co., Ltd | Patches for external use |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| JP2005516888A (ja) * | 2001-06-08 | 2005-06-09 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 過分極活性化型環状ヌクレオチド依存性チャンネルに標的を定めることによる疼痛の治療 |
| US20050176685A1 (en) * | 2002-04-05 | 2005-08-11 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| WO2005027921A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
| US20090035315A1 (en) * | 2004-06-17 | 2009-02-05 | Stephan Christgau | Method of Improving Treatments in Rheumatic and Arthritic Diseases |
| EP1890727B1 (en) * | 2005-05-25 | 2012-10-03 | CaloSyn Pharma, Inc | Method and composition for treating osteoarthritis |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| PT2049123E (pt) * | 2006-08-03 | 2013-03-06 | Horizon Pharma Ag | Tratamento de doença reumatóide com glucocorticóide de libertação retardada |
| US20100158905A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Combination therapy of arthritis with tranilast |
| MX2011011698A (es) * | 2009-05-04 | 2012-02-29 | Zars Pharma Inc | Metodo para tratar dolores asociados con neuroma, entrapamiento nervioso y otras condiciones. |
| US8946199B2 (en) | 2010-04-26 | 2015-02-03 | Ketan Desai | Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion |
-
2013
- 2013-03-08 US US13/791,685 patent/US9012432B2/en active Active - Reinstated
-
2014
- 2014-03-07 CN CN201480026349.0A patent/CN105324113B/zh active Active
- 2014-03-07 JP JP2015561747A patent/JP6839491B2/ja not_active Expired - Fee Related
- 2014-03-07 MX MX2015011671A patent/MX377447B/es active IP Right Grant
- 2014-03-07 KR KR1020157027348A patent/KR102253394B1/ko active Active
- 2014-03-07 AU AU2014225373A patent/AU2014225373B2/en active Active
- 2014-03-07 WO PCT/US2014/022169 patent/WO2014138712A1/en not_active Ceased
- 2014-03-07 CA CA2941346A patent/CA2941346C/en active Active
- 2014-03-07 BR BR112015021503-3A patent/BR112015021503B1/pt not_active IP Right Cessation
- 2014-03-07 ES ES14761174T patent/ES2904365T3/es active Active
- 2014-03-07 EA EA201591638A patent/EA032067B1/ru not_active IP Right Cessation
- 2014-03-07 EP EP14761174.3A patent/EP2964209B1/en active Active
-
2019
- 2019-04-03 JP JP2019071500A patent/JP2019104762A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX377447B (es) | 2025-03-10 |
| KR20150125001A (ko) | 2015-11-06 |
| CN105324113B (zh) | 2018-07-03 |
| EP2964209A1 (en) | 2016-01-13 |
| AU2014225373B2 (en) | 2018-07-05 |
| JP2019104762A (ja) | 2019-06-27 |
| JP2016510765A (ja) | 2016-04-11 |
| US20140256681A1 (en) | 2014-09-11 |
| KR102253394B1 (ko) | 2021-05-20 |
| EA032067B1 (ru) | 2019-04-30 |
| AU2014225373A1 (en) | 2015-10-22 |
| CA2941346C (en) | 2020-03-10 |
| EA201591638A1 (ru) | 2016-02-29 |
| BR112015021503A2 (en) | 2018-05-15 |
| US9012432B2 (en) | 2015-04-21 |
| ES2904365T3 (es) | 2022-04-04 |
| CN105324113A (zh) | 2016-02-10 |
| WO2014138712A1 (en) | 2014-09-12 |
| BR112015021503B1 (pt) | 2022-09-06 |
| EP2964209A4 (en) | 2016-08-03 |
| CA2941346A1 (en) | 2014-09-12 |
| JP6839491B2 (ja) | 2021-03-17 |
| EP2964209B1 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011671A (es) | Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. | |
| EA201790737A1 (ru) | Комбинированная терапия | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| MX2020011772A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MX380370B (es) | Modulador del receptor de androgeno y usos de este. | |
| UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
| CL2016000354A1 (es) | Modulación de la inmunidad tumoral | |
| MX2017013802A (es) | Métodos para tratar el cáncer. | |
| AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
| MX2016005294A (es) | Metodos para tratar y prevenir enfermedad injerto contra huésped. | |
| CL2016000055A1 (es) | Métodos para tratar o prevenir afecciones oftalmológicas | |
| EA201690206A1 (ru) | Терапевтически активные соединения и способы их применения | |
| CL2017000290A1 (es) | Inhibidores de la proteína kinasa c y métodos de su uso. | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| EP3141603A4 (en) | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective | |
| NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
| MX2015014344A (es) | Terapia contra el cancer. | |
| MX2016013245A (es) | Regimen de dosificacion de liberacion inmediata de moduladores s1p. | |
| MX2021007899A (es) | Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6. | |
| NI201500151A (es) | Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata. | |
| CR20140400A (es) | Terapia combinada para el tratamiento del cancer de ovario | |
| UY36286A (es) | Tratamientos médicos basados en anamorelina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |